Alcami to manufacture PharmaTher’s proprietary ketamine products

Three weeks after Alcami announced it was investing an additional $31 million to expand its sterile CDMO operation in Charleston, SC to increase its fill-finish and lyophilisation capacity, the company has agreed to manufacture PharmaTher's proprietary ketamine products.

PharmaTher, a clinical-stage psychedelics biotech company, is building a specialty ketamine-based product pipeline to support its internal product pipeline.

Alcami will support PharmaTher’s global ketamine product development and commercialisation plans by supplying expertise in GMP sterile fill-finish manufacturing and controlled substances.

The ability to manufacture and supply ketamine products in different dosage forms enables PharmaTher to guarantee delivery on its product pipeline as well as form partnerships with research labs, ketamine clinics and pharmaceutical companies that are seeking a secure supply of cGMP ketamine and ketamine products for current portfolios; exploring alternative dose forms for multiple existing indications; and requiring support to develop and commercialise specific ketamine products for new indications.

PharmaTher’s proprietary ketamine drug products are expected to be available for FDA Phase III clinical studies and commercial use during the latter half of 2022.

ABOUT ALCAMI

Alcami is a US-based CDMO for pharma and biotech companies with over 40 years of experience. Our goal is to support our clients in making their projects go from potential to reality day-after-day. Core capabilities include sterile fill-finish development & manufacturing, oral solid dose development & manufacturing, and laboratory services. For more information, visit alcaminow.com.